Morgan Stanley’s G1 Therapeutics GTHX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-401,481
Closed -$915K – 8071
2024
Q2
$915K Buy
401,481
+226,144
+129% +$864K ﹤0.01% 5016
2024
Q1
$757K Buy
175,337
+5,279
+3% +$18.4K ﹤0.01% 5120
2023
Q4
$519K Buy
170,058
+134,915
+384% +$254K ﹤0.01% 5273
2023
Q3
$50.6K Sell
35,143
-112,257
-76% -$217K ﹤0.01% 6164
2023
Q2
$367K Sell
147,400
-115,663
-44% -$316K ﹤0.01% 5369
2023
Q1
$705K Sell
263,063
-107,610
-29% -$517K ﹤0.01% 5058
2022
Q4
$2.01M Hold
370,673
– – ﹤0.01% 4461
2022
Q3
$4.22M Buy
338,294
+155,643
+85% +$1.78M ﹤0.01% 3832
2022
Q2
$903K Hold
182,651
– – ﹤0.01% 5076
2022
Q1
$2.09M Sell
274,958
-86,860
-24% -$824K ﹤0.01% 4492
2021
Q4
$3.69M Buy
361,818
+15,404
+4% +$196K ﹤0.01% 4036
2021
Q3
$4.65M Sell
346,414
-225,647
-39% -$3.68M ﹤0.01% 3795
2021
Q2
$12.6M Buy
572,061
+335,635
+142% +$7.46M ﹤0.01% 2725
2021
Q1
$5.69M Buy
236,426
+2,206
+0.9% +$51.3K ﹤0.01% 3274
2020
Q4
$4.21M Buy
234,220
+93,868
+67% +$1.4M ﹤0.01% 3441
2020
Q3
$1.62M Buy
140,352
+97,354
+226% +$1.61M ﹤0.01% 3842
2020
Q2
$1.04M Sell
42,998
-109,383
-72% -$1.81M ﹤0.01% 4139
2020
Q1
$1.68M Buy
152,381
+82,547
+118% +$1.54M ﹤0.01% 3513
2019
Q4
$1.84M Sell
69,834
-91,106
-57% -$2.13M ﹤0.01% 4108
2019
Q3
$3.67M Buy
160,940
+146,916
+1,048% +$4.63M ﹤0.01% 3212
2019
Q2
$430K Sell
14,024
-341,718
-96% -$7.19M ﹤0.01% 4683
2019
Q1
$5.91M Buy
355,742
+149,498
+72% +$2.84M ﹤0.01% 2546
2018
Q4
$3.95M Buy
206,244
+169,488
+461% +$6.35M ﹤0.01% 3162
2018
Q3
$1.92M Sell
36,756
-7,116
-16% -$388K ﹤0.01% 4036
2018
Q2
$1.91M Buy
43,872
+13,232
+43% +$567K ﹤0.01% 4122
2018
Q1
$1.14M Buy
30,640
+14,551
+90% +$388K ﹤0.01% 4456
2017
Q4
$319K Buy
16,089
+6,027
+60% +$130K ﹤0.01% 5223
2017
Q3
$250K Buy
10,062
+8,244
+453% +$152K ﹤0.01% 5239
2017
Q2
$32K Buy
+1,818
New +$31.8K ﹤0.01% 5974

Morgan Stanley's GTHX Position: Q3 2024 in Review

Morgan Stanley sold out of G1 Therapeutics (GTHX) in Q3 2024, closing a stake of 401,481 shares — an estimated $915K sold.

Morgan Stanley first reported a position in GTHX in Q2 2017 and held it in 29 quarters. The position peaked at $12.6M in Q2 2021. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.

  • Morgan Stanley reported no remaining G1 Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Morgan Stanley sold 401,481 G1 Therapeutics shares in Q3 2024, an estimated $915K.
  • Morgan Stanley first reported a position in G1 Therapeutics in Q2 2017 and held it in 29 quarters.
  • Morgan Stanley's G1 Therapeutics position peaked at $12.6M in Q2 2021.
  • 0 funds tracked by Wall St. Rank held G1 Therapeutics as of Q3 2024.

Based on Morgan Stanley's 13F filing for Q3 2024, filed 14 Nov 2024.